Genome Editing

Senior Directors: Derek Sant’Angelo, PhD and Yibin Kang, PhD

Managing Director: Peter Romanienko, PhD

Scientific Director: Ghassan Yehia, PhD

The Genome Editing shared resource at Rutgers Cancer Institute of New Jersey was established in 2016 as an institutionally managed shared resource led by Rutgers Office of Research and Economic Development under the Office of Research Advancement (ORAd). The shared resource also functions as an NCI-designated cancer center resource with joint scientific and administrative/fiscal oversight with Rutgers Cancer Institute of New Jersey. Its purpose is to provide a centralized laboratory for the generation and preservation of mouse research models and creation of custom genome edited cell lines.

Genome Editing Facility

In addition to its service functions, the shared resource plays an important intellectual role in the development and pursuit of mouse-oriented research projects and the application of genome editing throughout the Rutgers Cancer Institute’s consortium. The shared resource also engages in the development of new approaches and methodologies in genome editing to better serve its users.

The Genome Editing shared resource serves as one of America’s largest, most comprehensive university-based research centers. Its main facility is located in New Brunswick with a satellite site in Newark. Its main focus is to provide expertise and technical services required to manipulate the genomes of animals and various cell lines including human cells utilizing CRISPR-Cas9 mediated gene editing. Standard services such as mouse embryonic stem cell manipulation, in vitro fertilization, embryo or sperm cryopreservation, mouse rederivation, genotyping and breeding services are also offered. For additional information and to request services please visit:

Genome Editing Team



The Genome Editing shared resource of the Rutgers Cancer Institute of New Jersey are specialized service facilities that support the cancer research efforts of our members.

This facility is supported primarily by the Cancer Center Support Grant (CCSG) from the National Cancer Institute.  Additional support may be provided from other sources, such as chargeback systems, institutional funding and/or other grants. The support from the CCSG allows the facility to provide benefits to Cancer Center members, such as ensured access to services or subsidies to user rates.

Please remember to acknowledge the valuable services provided by the Genome Editing shared resource in your research papers, publications, and grant applications. The following acknowledgement statement is recommended:

"This research was supported by the Genome Editing shared resource of Rutgers Cancer Institute of New Jersey (P30CA072720)."

(Note: please also consider including the names of individuals from the shared resource if they provided any intellectual input or additional effort.)


precision medicine at Rutgers Cancer Institute












Proud member of
Big Ten Cancer Research Consortium



Rutgers Health